Therapeutic Potential of Acanthopanax trifoliatus Against COVID-19 and Pharyngitis: Computational and Experimental Insights

Study Background and Research Question

The ongoing COVID-19 pandemic, triggered by SARS-CoV-2, has posed unprecedented challenges to global health. Among the constellation of symptoms, pharyngitis (sore throat) is prevalent, especially in cases involving the Omicron variant, with incidence rates as high as 64% among symptomatic, PCR-positive patients according to the reference study. Conventional therapies, including antibiotics and analgesics, often fail to provide adequate symptom relief or address the multifactorial pathogenesis of COVID-19-associated pharyngitis. This therapeutic gap underscores the need for novel agents that can target both viral and inflammatory pathways.

Acanthopanax trifoliatus (L.) Merr (AT), a widely distributed Asian plant with a rich ethnomedical history, contains over 100 bioactive constituents such as polyphenols, saponins, and polysaccharides. While traditional use and some pharmacological studies suggest broad anti-inflammatory and antiviral effects, the molecular mechanisms and therapeutic targets relevant to COVID-19 and pharyngitis have remained poorly defined.

Key Innovation from the Reference Study

Chen et al. (2025) advance the field by integrating high-throughput in silico screening with targeted experimental validation to systematically evaluate AT’s potential against COVID-19 and pharyngitis. This dual-pronged strategy not only identifies promising molecular candidates but also validates their biological effects on relevant cellular and viral targets. The innovation lies in the comprehensive mapping of AT’s phytochemical interactions across multiple protein targets implicated in both diseases, moving beyond single-target paradigms common in earlier research.

Methods and Experimental Design Insights

The study begins with an extensive ligand library construction, encompassing major and minor constituents isolated from AT. Computational approaches—primarily molecular docking and virtual screening—are employed to predict binding affinities of AT-derived molecules for a panel of protein targets associated with SARS-CoV-2 replication and host inflammatory pathways. These targets include viral proteases, spike protein domains, and human proteins involved in cytokine release and tissue inflammation.

Top-scoring candidate compounds, notably rutin and isochlorogenic acid C, are selected for further in vitro validation. Experimental assays assess their ability to inhibit SARS-CoV-2 infection and modulate expression of key pro-inflammatory genes in relevant cellular models. The study also quantifies the degree of gene inhibition, with several targets showing over 50% downregulation upon treatment—a notable benchmark for both antiviral and anti-inflammatory efficacy.

Protocol Parameters

• Ligand library preparation: Comprehensive extraction and cataloging of AT’s major flavonoids, polyphenols, and saponins for virtual screening.
• Molecular docking: Use of high-resolution 3D structures of SARS-CoV-2 and host proteins to predict binding affinity of AT compounds.
• Experimental validation: In vitro assays measuring viral inhibition and gene expression modulation in cell lines relevant to respiratory inflammation.
• Gene expression quantification: Real-time PCR gene expression analysis to assess antiviral and anti-inflammatory effects (see below for practical qPCR workflow support).

Core Findings and Why They Matter

The reference paper reports that several AT-derived compounds, most notably rutin and isochlorogenic acid C, demonstrate high binding affinities to both viral and host targets in virtual screens. Subsequent experimental assays confirm these molecules exhibit strong inhibitory activity against SARS-CoV-2 and significantly reduce expression of genes linked to inflammation and tissue injury. Inhibition levels exceeding 50% for several key genes highlight their robust pharmacological potential.

These findings are significant for several reasons:

• Multi-target action: Unlike traditional antivirals or symptom suppressants, AT compounds modulate both viral replication and inflammatory damage, addressing the dual pathophysiology of COVID-19-related pharyngitis.
• Methodological efficiency: The successful integration of in silico and in vitro workflows demonstrates a rapid, resource-efficient pipeline for identifying and validating natural product therapeutics.
• Ethnopharmacological validation: The study provides molecular justification for traditional uses of AT in treating colds and sore throats, bridging empirical knowledge with mechanistic evidence.

Comparison with Existing Internal Articles

While the reference study focuses on natural product discovery and validation, related internal resources highlight practical aspects of gene expression quantification and workflow optimization using advanced reagents. For example, the article "HotStart 2X Green qPCR Master Mix: Precision in Toxicogenomics" details how robust SYBR Green qPCR master mix workflows enable reproducible real-time PCR gene expression analysis and RNA-seq validation, which are essential for verifying the gene modulation observed in studies like Chen et al. (2025).

Similarly, "Enhancing qPCR Reliability with HotStart™ 2X Green qPCR Master Mix" addresses specificity and reproducibility issues in nucleic acid quantification—technical challenges also encountered in the experimental validation phase of the reference study. These internal articles provide actionable strategies to translate complex multi-target pharmacology findings into reliable gene expression data, especially when using hot-start qPCR reagents to minimize non-specific amplification and primer-dimer artifacts.

Limitations and Transferability

Despite its strengths, several limitations temper the immediate translational potential of the findings. The majority of the mechanistic insights are derived from in silico models, which, while high-throughput, do not fully replicate the complexity of in vivo pharmacokinetics and target engagement. Experimental validation is confined to cell-based assays; thus, efficacy, safety, and pharmacodynamics in animal models or human subjects remain unaddressed. Furthermore, the multi-component nature of AT extracts may complicate standardization and regulatory approval for clinical application.

Nevertheless, the study’s workflow—combining computational screening with targeted experimental assays—offers a broadly transferable template for natural product drug discovery, especially where rapid response to emerging infectious diseases is required.

Why this cross-domain matters, maturity, and limitations

The bridge from traditional plant-based remedies to molecularly validated multi-target therapeutics is especially important in pandemic contexts where conventional single-target drugs may be insufficient. However, the maturity of this approach is still limited by gaps in clinical validation, and its use should be seen as complementary rather than a replacement for established therapies until further evidence is available.

Research Support Resources

To support researchers aiming to replicate or extend these findings—especially those quantifying gene expression changes as part of antiviral or anti-inflammatory studies—optimized reagents are essential. HotStart™ 2X Green qPCR Master Mix (SKU K1070) from APExBIO is a SYBR Green qPCR master mix incorporating antibody-mediated Taq polymerase hot-start inhibition. Its robust specificity and sensitivity make it well-suited for real-time PCR gene expression analysis, RNA-seq validation, and nucleic acid quantification workflows similar to those described in the reference study. For further optimization strategies and troubleshooting tips, researchers can consult scenario-driven guidance in internal articles such as "Enhancing qPCR Reliability with HotStart™ 2X Green qPCR Master Mix".